A novel canine favored CpG oligodeoxynucleotide capable of enhancing the efficacy of an inactivated aluminum-adjuvanted rabies vaccine of dog use

Vaccine

Volumn 28, Issue 12, 2010, Pages 2458-2464

  Ren, Jiling ^a   Sun, Luguo ^a   Yang, Liang ^a   Wang, Hua ^a   Wan, Min ^a   Zhang, Peiyin ^a   Yu, Hongtao ^b   Guo, Yan ^b   Yu, Yongli ^a   Wang, Liying ^a  

^a Jilin University   (China)

^b Changchun Institute of Biological Products   (China)

Author keywords

CpG ODN; Dog; Rabies vaccine

Indexed keywords

ALUMINUM; CPG OLIGODEOXYNUCLEOTIDE; INACTIVATED VACCINE; KENNEL COUGH VACCINE; RABIES VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOG; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABIES; SPLEEN CELL; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM; ANIMALS; ANTIBODIES, VIRAL; CELLS, CULTURED; DOG DISEASES; DOGS; FEMALE; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; RABIES; RABIES VACCINES; SPLEEN;

EID: 77249134997     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.077     Document Type: Article

References (30)

1. WHO Expert Consultation on Rabies. First report. Geneva: World Health Organization; 2004. (WHO Technical Report Series; 931).
2. Hu R., Tang Q., Tang J., and Fooks A.R. Rabies in China: an update. Vector Borne Zoonotic Dis 9 1 (2009) 1-12
3. Bellotto A.J. Organization of mass vaccination for dog rabies in Brazil. Rev Infect Dis 10 Suppl. 4 (1988) S693-S696
4. Sage G., Khawplod P., Wilde H., Lobaugh C., Hemachudha T., Tepsumethanon W., et al. Immune response to rabies vaccine in Alaskan dogs: failure to achieve a consistently protective antibody response. Trans R Soc Trop Med Hyg 87 5 (1993) 593-595
5. Minke J.M., Bouvet J., Cliquet F., Wasniewski M., Guiot A.L., Lemaitre L., et al. Comparison of antibody responses after vaccination with two inactivated rabies vaccines. Vet Microbiol 133 3 (2009) 283-286
6. Suzuki K., González E.T., Ascarrunz G., Loza A., Pérez M., Ruiz G., et al. Antibody response to an anti-rabies vaccine in a dog population under field conditions in Bolivia. Zoonoses Public Health 55 8-10 (2008) 414-420
7. Tepsumethanon W., Polsuwan C., Lumlertdaecha B., Khawplod P., Hemachudha T., Chutivongse S., et al. Immune response to rabies vaccine in Thai dogs: a preliminary report. Vaccine 9 9 (1991) 627-630
8. Chisari F.V., and Cytotoxic. T cells and viral hepatitis. J Clin Invest 99 7 (1997) 1472-1477
9. Rehermann B., and Intrahepatic. T cells in hepatitis B: viral control versus liver cell injury. J Exp Med 191 8 (2000) 1263-1268
10. Yoneda A., Tuchiya K., Takashima Y., Arakawa T., Tsuji N., Hayashi Y., et al. Protection of mice from rabies by intranasal immunization with inactivated rabies virus. Exp Anim 57 1 (2008) 1-9
11. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 6522 (1995) 546-549
12. Yi A.K., Chang M., Peckham D.W., Krieg A.M., and Ashman R.F. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol 160 12 (1998) 5898-5906
13. Hartmann G., Weiner G.J., and Krieg A.M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 96 16 (1999) 9305-9310
14. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., and Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186 10 (1997) 1623-1631
15. Klinman D.M., Barnhart K.M., and Conover J. CpG motifs as immune adjuvants. Vaccine 17 1 (1999) 19-25
16. Davis H.L., Suparto I.I., Weeratna R.R., Jumintarto, Iskandriati D.D., Chamzah S.S., et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18 18 (2000) 1920-1924
17. Hartmann G., Weeratna R.D., Ballas Z.K., Payette P., Blackwell S., Suparto I., et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164 3 (2000) 1617-1624
18. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Adhami M.A., Krieg A.M., et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24 6 (2004) 693-701
19. Rankin R., Pontarollo R., Gomis S., Karvonen B., Willson P., Loehr B.I., et al. CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. Vaccine 20 23-24 (2002) 3014-3022
20. Wang X., Bao M., Wan M., Wei H., Wang L., Yu H., et al. A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine. Vaccine 26 15 (2008) 1893-1901
21. Kurata K., Iwata A., Masuda K., Sakaguchi M., Ohno K., and Tsujimoto H. Identification of CpG oligodeoxynucleotide sequences that induce IFN-gamma production in canine peripheral blood mononuclear cells. Vet Immunol Immunopathol 102 4 (2004) 441-450
22. Wernette C.M., Smith B.F., Barksdale Z.L., Hecker R., and Baker H.J. CpG oligodeoxyucleotides stimulate canine and feline immune cell proliferation. Vet Immunol Immunopathol 84 3-4 (2002) 223-236
23. Krieg A.M., Hartmann G., and Yi A.K. Mechanisms of action of CpG DNA. Curr Top Microbiol Immunol 247 (2000) 1-21
24. Hartmann G., and Krieg A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 164 2 (2000) 944-953
25. Kamstrup S., Verthelyi D., and Klinman D.M. Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeognuleotides. Vet Microbiol 78 4 (2001) 353-362
26. Lee K.W., Jung J., Lee Y., Kim T.Y., Choi S.Y., Park J., et al. Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol Immunol 43 13 (2006) 2107-2118
27. Ioannou X.P., Gomis S.M., Karvonen B., Hecker R., Babiuk L.A., and van Drunen Littel-van den Hurk S. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21 1-2 (2002) 127-137
28. Ioannou X.P., Griebel P., Hecker R., Babiuk L.A., and van Drunen Littel-van den Hurk S. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol 76 18 (2002) 9002-9010
29. Linghua Z., Xingshan T., and Fengzhen Z. The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo. Int immunopharmacol 6 8 (2006) 1267-1276
30. Stacey K.J., Blackwell J.M., and Immunostimulatory. DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 67 8 (1999) 3719-3726